125 related articles for article (PubMed ID: 15566511)
21. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Nakai K; Saito T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Intervirology; 2003; 46(5):296-307. PubMed ID: 14555850
[TBL] [Abstract][Full Text] [Related]
22. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years.
Lee HJ; Yeon JE; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Kim JH; Seo YS; Yim HJ; Byun KS
Intervirology; 2015; 58(1):14-21. PubMed ID: 25592614
[TBL] [Abstract][Full Text] [Related]
24. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
25. SEN virus infection influences the pathological findings in liver but does not affect the incidence of hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis.
Moriyama M; Mikuni M; Matsumura H; Nakamura H; Oshiro S; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Tanaka N; Arakawa Y
Liver Int; 2005 Apr; 25(2):226-35. PubMed ID: 15780043
[TBL] [Abstract][Full Text] [Related]
26. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area.
Huang YH; Wu JC; Chen CH; Chang TT; Lee PC; Chau GY; Lui WY; Chang FY; Lee SD
Liver Int; 2005 Apr; 25(2):236-41. PubMed ID: 15780044
[TBL] [Abstract][Full Text] [Related]
27. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
28. The natural history of chronic hepatitis B: a retrospective study.
Wu GC; Zhou WP; Zhao YR; Guo SH; Wang ZY; Zou SB; Zhang QH; Ren H; Huang AL; Zhang DF
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):566-70. PubMed ID: 14627521
[TBL] [Abstract][Full Text] [Related]
29. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment.
Miyajima I; Sata M; Kumashiro R; Uchimura Y; Ide T; Suzuki H; Tanikawa K
Oncol Rep; 1998; 5(1):201-4. PubMed ID: 9458322
[TBL] [Abstract][Full Text] [Related]
30. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
31. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
32. Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy.
Hayashi K; Kumada T; Nakano S; Takeda I; Kiriyama S; Sone Y; Toyoda H; Shimizu H; Honda T
Hepatogastroenterology; 2002; 49(44):508-12. PubMed ID: 11995484
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
[TBL] [Abstract][Full Text] [Related]
34. Interferon therapy improves the irregular regeneration of hepatocytes in liver in patients with C-viral chronic hepatitis and liver cirrhosis.
Moriyama M; Matsumura H; Oshiro S; Nakamura H; Arakawa Y; Nirei K; Aoki H; Yamagami H; Kaneko M; Tanaka N; Arakawa Y
Intervirology; 2007; 50(2):138-49. PubMed ID: 17191016
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein.
Sato S; Genda T; Ichida T; Amano N; Sato S; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Hirano K; Shimada Y; Iijima K; Wada R; Nagahara A; Watanabe S
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999409
[TBL] [Abstract][Full Text] [Related]
36. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
[TBL] [Abstract][Full Text] [Related]
37. Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.
Matsumura H; Nirei K; Nakamura H; Higuchi T; Arakawa Y; Ogawa M; Tanaka N; Moriyama M
World J Gastroenterol; 2013 Aug; 19(30):4887-96. PubMed ID: 23946593
[TBL] [Abstract][Full Text] [Related]
38. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
[TBL] [Abstract][Full Text] [Related]
39. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection.
Lai MS; Hsieh MS; Chiu YH; Chen TH
Hepatology; 2006 Jun; 43(6):1295-302. PubMed ID: 16729295
[TBL] [Abstract][Full Text] [Related]
40. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
